Email this article Secondary diseases and Burkitt’s lymphoma in HIV-infected patients
- Authors: Mikhailova NR1, Ermak TE2, Anikeev AA3
-
Affiliations:
- «Оренбургский государственный медицинский университет» Минздрава России
- «Центральный НИИ эпидемиологии» Роспотребнадзора
- Федеральная служба исполнения наказаний
- Issue: Vol 87, No 11 (2015)
- Pages: 97-98
- Section: Editorial article
- URL: https://ogarev-online.ru/0040-3660/article/view/31872
- ID: 31872
Cite item
Abstract
The authors give the clinical data of 110 human immunodeficiency virus (HIV)-infected patients who stayed in a correctional facility during 2014. Of the examinees, there were almost 50% of the patients with advanced stages (IVA—IVB) with different secondary/opportunistic diseases, among which was Burkitt’s lymphoma, a rather rare malignant disease that developed in obvious immunodeficiency in the absence of antiretroviral therapy.
About the authors
N R Mikhailova
«Оренбургский государственный медицинский университет» Минздрава РоссииОренбург, Россия
T E Ermak
«Центральный НИИ эпидемиологии» РоспотребнадзораМосква, Россия
A A Anikeev
Федеральная служба исполнения наказанийОренбург, Россия
References
- ВИЧ-инфекция и СПИД. Национальное руководство. Под ред. Покровского В.В. Краткое издание. М.: ГЭОТАР-Медиа; 2014.
- Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. М.: Р. Валент; 2010.
- Zoufaly A, Stellbrink HJ, der Heiden M. Insufficient virus suppression during HAART is a strong predictor for the development of AIDS-related lymphoma. Abstract 16, 15th CROI 2008, Boston.
- Levine AM. AIDS-related lymphoma: clinical aspects. Semin Oncol. 2000;27:442-453.
- Hoffmann C, Wolf E, Fatkenheuer G. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521-1529.
- Lim ST, Karim R, Nathwani BN. AIDS-related Burkitt,s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430-4438.
Supplementary files
